JUNE 2, 2025

MAD-ID 2025

Rapid Diagnostic Testing with BCID2 Panel Improves Time to Optimal Therapy

By Gina Shaw

More than half of patients with positive cultures for bloodstream infections achieved optimal therapy within 48 hours using the Biofire Blood Culture Identification 2 (BCID2; bioMérieux) panel, a rapid multiplex polymerase chain reaction–based diagnostic platform, in a single-center retrospective cohort study presented at MAD-ID 2025, in Orlando, Fla.

The study, conducted at Brigham and Women’s Hospital, in Boston, included hospitalized adult patients with at least